Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology
+$1.11 today
- Market cap
- $4.45B
- Beta
- 0.30
- P/E (TTM)
- -21.9
- EPS (TTM)
- -$1.64
Volume 0.87M
Average 1.32M
EWTX Net Income
Bottom-line profit after all expenses, interest, and taxes.
Edgewise Therapeutics, Inc.NASDAQ: EWTX
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income turns positive
Q3 FY2026 net income was $1.17B, compared with -$40.67M a year earlier. Trailing-twelve-month net income was $1.01B.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$208.14M (-24.0%) for the fiscal year ending Dec 2026, a step up from the -25.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $1.17B+2134.2% QoQ
- Last fiscal yearDec 2025
- -$167.8M-25.4% YoY
- LTMSep 2026
- $1.01B+742.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2967.6% | +0.7% | -2966.9 pp |
| 1 year | -25.4% | -24.0% | +1.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (167.8M) USD
- Year-over-year change
- -25.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (167.8M) | -25.4% |
| FY2024 | 2024-12-31 | (133.81M) | -33.6% |
| FY2023 | 2023-12-31 | (100.16M) | -48.1% |
| FY2022 | 2022-12-31 | (67.64M) | -58.0% |
| FY2021 | 2021-12-31 | (42.81M) | — |
Net Income vs competitors
How EWTX compares with its peers on the latest reported figures
- EWTX's LTM Sep 2026 net income of $1.01B is the highest of the 10 companies compared; the peer median is -$166.01M.
- Its year-over-year change of +742.1% is the highest of 10, against a peer median of -74.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.01B | +742.1% | — | — | |
| LTM Mar 2026 | $65.06M | +126.2% | — | 3.0% | |
| LTM Jun 2026 | -$38.38M | -106.1% | — | 3.8% | |
| LTM Mar 2026 | -$77.22M | +24.4% | — | — | |
| LTM Mar 2026 | -$114.59M | -108.1% | — | — | |
| LTM Mar 2026 | -$166.01M | -74.3% | — | — | |
| LTM Mar 2026 | -$166.12M | -770.3% | — | 2895.1% | |
| LTM Mar 2026 | -$169.77M | -437.7% | — | 529.2% | |
| LTM Mar 2026 | -$191.78M | -37.3% | — | — | |
| LTM Jun 2026 | -$519.41M | -25.8% | — | — | |
| Peer median (excluding EWTX) | -$166.01M | -74.3% | — | 266.5% | |
Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.27M |
| Gross Profit | 0 | 0 | 0 | 0 | (2.27M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.19M | 54.03M | 90.91M | 126.97M | 151.39M |
| Selling, General & Admin | 11.03M | 17.63M | 23.45M | 31.87M | 40.02M |
| Operating Expenses | 43.22M | 71.66M | 114.36M | 158.83M | 189.14M |
| Depreciation & Amortization | 272K | 538K | 1.73M | 2.29M | 2.27M |
| EBITDA | (42.54M) | (63.08M) | (98.43M) | (131.52M) | (165.53M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.22M) | (71.66M) | (114.36M) | (158.83M) | (191.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 402K | 2.66M | 14.19M | 25.02M | 23.61M |
| Interest Expense | 0 | 4.02M | 0 | 0 | 0 |
| Other Income / Expenses | 402K | 4.02M | 14.19M | 25.02M | 23.61M |
| Income Before Tax | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| EPS (Diluted) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| Weighted Avg Shares | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
| Weighted Avg Shares (Diluted) | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Intrinsic Alpha fair value
Locked
Current Price
$41.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.